Cowen and Company restated their buy rating on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a research report released on Thursday.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Other equities analysts have also issued research reports about the stock. Leerink Swann reissued a buy rating on shares of Alexion Pharmaceuticals in a report on Tuesday, June 7th. Oppenheimer Holdings Inc. reaffirmed a buy rating and issued a $221.00 target price (down from $228.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Brean Capital reaffirmed a buy rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. BMO Capital Markets reaffirmed a buy rating and issued a $160.00 target price (down from $168.00) on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. Finally, Vetr lowered shares of Alexion Pharmaceuticals from a strong-buy rating to a buy rating and set a $171.50 target price for the company. in a research note on Thursday, June 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $178.73.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 131.01 on Thursday. The stock has a 50 day moving average price of $131.05 and a 200-day moving average price of $135.80. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45. The company has a market capitalization of $29.38 billion, a price-to-earnings ratio of 329.17 and a beta of 1.08.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The firm earned $753 million during the quarter, compared to analyst estimates of $743.18 million. During the same period last year, the firm earned $1.44 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 18.4% on a year-over-year basis. Equities analysts predict that Alexion Pharmaceuticals will post $4.65 earnings per share for the current year.

In related news, CFO Vikas Sinha sold 277 shares of the stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $37,987.78. Following the sale, the chief financial officer now owns 178,463 shares in the company, valued at approximately $24,474,415.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alvin S. Parven sold 15,000 shares of the stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the sale, the director now owns 6,373 shares in the company, valued at approximately $870,105.69. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

A number of hedge funds have recently modified their holdings of ALXN. Legal & General Group Plc raised its stake in shares of Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares in the last quarter. Gateway Investment Advisers LLC raised its stake in shares of Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares in the last quarter. Strs Ohio raised its stake in shares of Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares in the last quarter. Finally, MAI Capital Management raised its stake in shares of Alexion Pharmaceuticals by 46.5% in the second quarter. MAI Capital Management now owns 4,281 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 1,358 shares in the last quarter. Hedge funds and other institutional investors own 96.34% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.